Hostname: page-component-cd9895bd7-lnqnp Total loading time: 0 Render date: 2024-12-23T06:26:12.205Z Has data issue: false hasContentIssue false
  • English
  • Français

Management of advanced hypopharyngeal carcinoma: systematic review of survival following surgical and non-surgical treatments

Published online by Cambridge University Press:  12 June 2018

A Habib
A Habib*
Affiliation:
Department of Ear, Nose and Throat, Nottingham University Hospitals NHS Trust, Nottingham City Hospital, UK
*
Address for correspondence: Dr Ayaaz Habib, Department of Ear, Nose and Throat, Nottingham University Hospitals NHS Trust, Nottingham City Hospital, Hucknall Road, Nottingham NG5 1PB, UK E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Background:

Advanced hypopharyngeal carcinoma has a dismal prognosis. The optimal treatment for these patients remains under debate. This systematic review aimed to compare survival following surgical and non-surgical treatments.

Methods:

A systematic review was conducted of randomised studies, with a descriptive analysis of retrospective observational studies.

Results:

Two randomised trials and 11 observational studies were included in the review. A meta-analysis of randomised trials reported a hazard ratio of 0.89 for overall survival in favour of surgical treatment (p = 0.44). Neither treatment was favoured in terms of overall survival. Observational studies did not report a survival advantage with either treatment. The five-year larynx preservation rates for non-surgically treated patients were between 38 and 58 percent.

Conclusion:

Chemoradiotherapy offers similar survivorship compared to surgery in advanced disease, while also making larynx preservation feasible. It can be used as a treatment in all patients as an alternative to surgery.

Keywords

HypopharynxCarcinomaSurvivalSurgical Procedures, OperativeConcurrent ChemoradiotherapyLarynxOrgan Preservation
Type
Review Articles
Information
The Journal of Laryngology & Otology , Volume 132 , Issue 5 , May 2018 , pp. 385 - 400
Copyright
Copyright © JLO (1984) Limited 2018 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1Hall, SF, Groome, PA, Irish, J, O'Sullivan, B. The natural history of patients with squamous cell carcinoma of the hypopharynx. Laryngoscope 2008;118:1362–71.CrossRefGoogle ScholarPubMed
2Edge, SB, Byrd, DR, Compton, C, Fritz, AG, Greene, FL, Trotti, A 3rd, eds. AJCC Cancer Staging Manual, 7th edn. New York: Springer, 2010.Google Scholar
3Edge, SB, Compton, CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of the TNM. Ann Surg Oncol 2010;17:1471–4.Google Scholar
4Hoffman, HT, Karnell, LH, Shah, JP, Ariyan, S, Brown, GS, Fee, WE et al. Hypopharyngeal cancer patient care evaluation. Laryngoscope 1997;107:1005–17.Google Scholar
5Pingree, TF, Davis, RK, Reichman, O, Derrick, L. Treatment of hypopharyngeal carcinoma: a 10 year review of 1,362 cases. Laryngoscope 1987;97:901–4.CrossRefGoogle Scholar
6Wahlberg, PC, Andersson, KE, Biorklund, AT, Moller, TR. Carcinoma of the hypopharynx: analysis of incidence and survival in Sweden over a 30-year period. Head Neck 1998;20:714–19.Google Scholar
7Frank, JL, Garb, JL, Kay, S, McClish, DK, Bethke, KP, Lind, DS et al. Postoperative radiotherapy improves survival in squamous cell carcinoma of the hypopharynx. Am J Surg 1994;168:476–80Google Scholar
8Takes, RP, Strojan, P, Silver, CE, Bradley, PJ, Haigentz, M Jr, Wolf, GT et al. Current trends in initial management of hypopharyngeal cancer: the declining use of open surgery. Head Neck 2012;34:270–81.Google Scholar
9Reis, I, Aguiar, A, Alzamora, C, Ferreira, C, Castro, V, Soares, A et al. Locally advanced hypopharyngeal squamous cell carcinoma: single-institution outcomes in a cohort of patients curatively treated either with or without larynx preservation. Radiol Bras 2016;49:21–5.CrossRefGoogle ScholarPubMed
10Bova, R, Goh, R, Poulson, M, Coman, WB. Total pharyngolaryngectomy for squamous cell carcinoma of the hypopharynx: a review. Laryngoscope 2005;115:864–9.CrossRefGoogle ScholarPubMed
11Lefebvre, JL, Chevalier, D, Luboinski, B, Kirkpatrick, A, Collete, L, Sahmoud, T. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 1996;88:890–9.Google ScholarPubMed
12Department of Veterans Affairs Laryngeal Cancer Study Group, Wolf, GT, Fisher, SG, Hong, WK, Hillman, R, Spaulding, M. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1991;324:1685–90.Google Scholar
13Adelstein, DJ, Li, Y, Adams, GL, Wagner, H Jr, Kish, JA, Ensley, JF et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003;21:92–8.Google Scholar
14Vokes, EE, Kies, MS, Haraf, DJ, Stenson, K, List, M, Humerickhouse, R et al. Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer. J Clin Oncol 2000;18:1652–61.Google Scholar
15Altundag, O, Gullu, I, Altundag, K, Yalcin, S, Ozyar, E, Cengiz, M et al. Induction chemotherapy with cisplatin and 5-fluorouracil followed by chemoradiotherapy or radiotherapy alone in the treatment of locoregionally advanced resectable cancers of the larynx and hypopharynx: results of single-center study of 45 patients. Head Neck 2005;27:15–21.CrossRefGoogle ScholarPubMed
16Shin, DM, Glisson, BS, Khuri, FR, Lippman, SM, Ginsberg, L, Diaz, E Jr et al. Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck. Cancer 2002;95:322–30.CrossRefGoogle ScholarPubMed
17Robson, A. Evidence-based management of hypopharyngeal cancer. Clin Otolaryngol 2002;27:413–20.Google Scholar
18American Joint Committee on Cancer. Manual for Staging of Cancer, 3rd edn. Philadelphia: Lippincott, 1988.Google Scholar
19PubMed, US National Library of Medicine, National Institutes of Health. In: https://www.ncbi.nlm.nih.gov/pubmed/ [5 January 2017].Google Scholar
20Embase (produced by Elsevier). In: https://www.elsevier.com/solutions/embase-biomedical-research [6 January 2017].Google Scholar
21Scopus. In: https://www.scopus.com/home.uri [6 January 2017]Google Scholar
22Cochrane Library. In: http://www.cochranelibrary.com/ [6 January 2017]Google Scholar
23Ovid technologies (Wolters Kluwer). In: http://www.ovid.com/site/index.jsp [7 January 2017]Google Scholar
24RefWorks. In: https://www.refworks.com/refworks2/default.aspx?r=authentication::init [7 January 2017]Google Scholar
25Moher, D, Liberati, A, Tetzlaff, J, Altman, DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.Google Scholar
26Vandersteen, C, Benezery, K, Chamorey, E, Ettaiche, M, Dassonville, O, Poissonnet, G et al. Contemporary therapeutic management of locally advanced hypopharyngeal cancer: oncologic and functional outcomes - a report on 100 cases. Acta Otolaryngol 2015;135:193–200.Google Scholar
27Chang, MF, Wang, H, Kang, C, Huang, S, Lin, C, Fang, K et al. Treatment results for hypopharyngeal cancer by different treatment strategies and its secondary primary--an experience in Taiwan. Radiat Oncol 2010;5:91.CrossRefGoogle ScholarPubMed
28Equator Network. Enhancing the QUAlity and Transparency Of health Research. In: http://www.equator-network.org/ [20 January 2017]Google Scholar
29CONSORT 2010. In: http://www.consort-statement.org/consort-2010 [20 January 2017]Google Scholar
30STROBE Statement. Strengthening the reporting of observational studies in epidemiology. In: https://www.strobe-statement.org/index.php?id=available-checklists [20 January 2017]Google Scholar
31Review Manager (RevMan) [computer program]. Version 5.3. Copenhagen: Nordic Cochrane Centre, Cochrane Collaboration, 2014.Google Scholar
32Higgins, JP, Green, S, eds. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0 [updated March 2011]. Cochrane Collaboration, 2011.Google Scholar
33Beauvillain, C, Mahe, M, Bourdin, S, Peuvrel, P, Bergerot, P, Rivière, A et al. Final results of a randomized trial comparing chemotherapy plus radiotherapy with chemotherapy plus surgery plus radiotherapy in locally advanced resectable hypopharyngeal carcinomas. Laryngoscope 1997;107:648–53.CrossRefGoogle ScholarPubMed
34Zelefsky, MJ, Kraus, DH, Pfister, DG, Raben, A, Shah, JP, Strong, EW et al. Combined chemotherapy and radiotherapy versus surgery and postoperative radiotherapy for advanced hypopharyngeal cancer. Head Neck 1996;18:405–11.Google Scholar
35Kim, JW, Kim, MS, Kim, S, Kim, JH, Lee, CG, Kim, GE et al. Definitive chemoradiotherapy versus surgery followed by adjuvant radiotherapy in resectable stage III/IV hypopharyngeal cancer. Cancer Res Treat 2016;48:45–53.Google Scholar
36Jang, JY, Kim, E, Cho, J, Jung, J, Oh, D, Ahn, YC et al. Comparison of oncological and functional outcomes between initial surgical versus non-surgical treatments for hypopharyngeal cancer. Ann Surg Oncol 2016;23:2054–61.CrossRefGoogle ScholarPubMed
37Lee, M, Ho, H, Hsiao, S, Hwang, J, Lee, C, Hung, S. Treatment results and prognostic factors in locally advanced hypopharyngeal cancer. Acta Otolaryngol 2008;128:103–9.CrossRefGoogle ScholarPubMed
38Hung, SK, Chen, H, Hsieh, C, Hsu, W, Chang, K, Liu, D et al. Treatment of advanced hypopharyngeal cancer - comparison of two modalities. Tzu Chi Med J 2006;18:15–21.Google Scholar
39Kim, S, Wu, H, Heo, D, Kim, K, Sung, M, Park, C. Advanced hypopharyngeal carcinoma treatment results according to treatment modalities. Head Neck 2001;23:713–17.Google Scholar
40Huang, W, Jen, Y, Chen, C, Su, Y, Lin, C, Lin, Y et al. Intensity modulated radiotherapy with concurrent chemotherapy for larynx preservation of advanced resectable hypopharyngeal cancer. Radiat Oncol 2010;5:37.Google Scholar
41Harris, BN, Biron, VL, Donald, P, Farwell, G, Luu, Q, Bewley, A et al. Primary surgery vs chemoradiation treatment of advanced-stage hypopharyngeal squamous cell carcinoma. JAMA Otolaryngol Head Neck Surg 2015;141:636–40.CrossRefGoogle ScholarPubMed
42Karnofsky Performance Status Scale Definitions Rating (%) Criteria. In: http://www.hospicepatients.org/karnofsky.html [21 February 2018]Google Scholar
43American Society of Anesthesiologists. ASA Physical Status Classification System. In: https://www.asahq.org/resources/clinical-information/asa-physical-status-classification-system [21 February 2018]Google Scholar
44Argiris, A. Induction chemotherapy for head and neck cancer: will history repeat itself? J Natl Compr Canc Netw 2005;3:393–403.CrossRefGoogle Scholar
45Brockstein, B, Haraf, DJ, Rademaker, AW, Kies, MS, Stenson, KM, Rosen, F et al. Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience. Ann Oncol 2004;15:1179–86.Google Scholar
46Pignon, JP, Bourhis, J, Domenge, C, Designe, L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: 3 meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000;355:949–55.Google Scholar
47Hitt, R, Lopez-Pousa, A, Martinez-Trufero, J, Escrig, V, Carles, J, Rizo, A et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 2005;23:8636–45.Google Scholar
48Posner, MR, Hershock, DM, Blajman, CR, Mickiewicz, E, Winquist, E, Gorbounova, V et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007;357:1705–15.Google Scholar
49Vermorken, JB, Remenar, E, Herpen, C, Gorlia, T, Mesia, R, Degardin, M et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007;357:1695–704.Google Scholar
50Forastiere, AA, Goepfert, H, Maor, M, Pajak, TF, Weber, R, Morrison, W et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003;349:2091–8.Google Scholar
51Prades, JM, Lallemant, B, Garrel, R, Reyt, E, Righini, C, Schmitt, T et al. Randomized phase III trial comparing induction chemotherapy followed by radiotherapy to concomitant chemoradiotherapy for laryngeal preservation in T3M0 pyriform sinus carcinoma. Acta Otolaryngol 2010;130:150–5.Google Scholar
52Bernier, J, Vermorken, JB, Koch, WM. Adjuvant therapy in patients with resected poor-risk head and neck cancer. J Clin Oncol 2006;24:2629–35.Google Scholar
53Bernier, J, Domenge, C, Ozsahin, M, Matuszewska, K, Lefebvre, JL, Greiner, RH et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004;350:1945–52.CrossRefGoogle ScholarPubMed
54Cooper, JS, Pajak, TF, Forastiere, AA, Jacobs, J, Campbell, BH, Saxman, SB et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004;350:1937–44.CrossRefGoogle ScholarPubMed
55Ensley, J, Crissman, J, Kish, J, Jacobs, J, Weaver, A, Kinzie, J et al. The impact of conventional morphologic analysis on response rates and survival in patients with advanced head and neck cancers treated initially with cisplatin-containing combination chemotherapy. Cancer 1986;57:711–17.Google Scholar
56Rooney, M, Kish, J, Jacobs, J, Kinzie, J, Weaver, A, Crissman, J et al. Improved complete response rate and survival in advanced head and neck cancer after 3-course induction therapy with 120-hour 5-FU infusion and cisplatin. Cancer 1985;55:1123–8.Google Scholar
57Schuller, DE, Wilson, HE, Smith, RE, Batley, F, James, AD. Preoperative reductive chemotherapy for locally advanced carcinoma of the oral cavity, oropharynx, and hypopharynx. Cancer 1983;51:15–19.3.0.CO;2-2>CrossRefGoogle ScholarPubMed
58Cohen, EE, Karrison, TG, Kocherginsky, M. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol 2014;32:2735–43.CrossRefGoogle ScholarPubMed
59Haddad, R, O'Neill, A, Rabinowits, G. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase III trial. Lancet Oncol 2013;14:257–64.Google Scholar
60De Pooter, CM, Scalliet, PG, Elst, HJ, Huybrechts, JJ, Gheuens, E, Oosterom, A et al. Resistance patterns between cis-diamminedichloroplatinum (II) and ionizing radiation. Cancer Res 1991;51:4523–7.Google Scholar